Related Experiment Video

Updated: Dec 31, 2025

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

19.2K

Complexities in the medical management of hypoglycaemia due to congenital hyperinsulinism

Christopher Worth1, Daphne Yau1,2, Maria Salomon Estebanez1

  • 1Department of Paediatric Endocrinology, Royal Manchester Children's Hospital, Manchester, UK.

Clinical Endocrinology
|January 10, 2020
PubMed

Insights

Congenital Hyperinsulinism (CHI) is a severe condition causing recurrent hypoglycemia in children. Effective management involves prompt treatment, individualized plans, and considering surgery to prevent neurodisability.

Area of Science:

  • Pediatrics
  • Endocrinology
  • Metabolic Disorders

Background:

  • Congenital Hyperinsulinism (CHI) is a rare genetic disorder characterized by persistent hypoglycemia.
  • It is the leading cause of recurrent, severe hypoglycemia in children, often leading to significant neurodevelopmental impairment.
  • Current treatment options for CHI are limited, with narrow therapeutic windows and potential for serious side effects.

Purpose of the Study:

  • To outline a comprehensive therapeutic strategy for managing Congenital Hyperinsulinism.
  • To emphasize the importance of individualized treatment plans for optimizing glycaemic stability and neurological outcomes.
  • To discuss the role of medication adjustment, withdrawal, and surgical intervention in CHI management.

Main Methods:

  • This review synthesizes current knowledge on CHI management strategies.
  • It focuses on prompt recognition and treatment of hypoglycemia.
  • The strategy emphasizes individualized glycaemic control, minimizing side effects, and considering disease progression.

Main Results:

  • Individualized treatment plans are crucial for achieving glycaemic stability in CHI patients.
  • Medication adjustments and potential withdrawal are key to optimizing safety and tolerability over time.
  • Pancreatic surgery is a viable option in specific cases to improve long-term outcomes.

Conclusions:

  • Optimal management of CHI requires a proactive, individualized approach focusing on glycaemic control and neuroprotection.
  • Treatment strategies must adapt to potential disease severity reduction over time.
  • A multidisciplinary approach, including consideration of surgical options, is essential for best patient outcomes.

Keywords:
congenital hyperinsulinismglucosehypoglycaemiainsulinmanagementmedication

More Related Videos

Author Spotlight: Investigating the Blood Glucose Homeostasis in Murine Brain Using a Cost-Effective Hyperglycemic And Hypoglycemic Clamp Technique07:35

Author Spotlight: Investigating the Blood Glucose Homeostasis in Murine Brain Using a Cost-Effective Hyperglycemic And Hypoglycemic Clamp Technique

Published on: January 26, 2024

2.0K
Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice11:10

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice

Published on: November 16, 2011

95.5K

Related Concept Videos

Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
743
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
4.7K
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.2K
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
607
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
3.0K
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
804